Effect of fluconazole on indinavir pharmacokinetics in human immunodeficiency virus-infected patients

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 2, 1998, Pages 223-227

  De Wit, S ^a   Debier, M ^a   De Smet, M ^b   McCrea, J ^b   Stone, J ^b   Carides, A ^b   Matthews, C ^b   Deutsch, P ^b   Clumeck, N ^a  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; FLUCONAZOLE; INDINAVIR;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; FLUCONAZOLE; HIV PROTEASE INHIBITORS; HIV SEROPOSITIVITY; HUMANS; INDINAVIR; MALE; MIDDLE AGED;

EID: 0031942594     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Balani, S., E. Woolf, V. Hoagland, M. Sturgill, P. Deutsch, K. Yeh, and J. H. Lin. 1996. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans. Drug Metab. Dispos. 24:1389-1394.
2. Chiba, M., M. Hensleigh, J. Nishime, S. Balani, and J. Lin. 1996. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos. 24:307-314.
3. Debruyne, D., and J. P. Ryckelynck. 1993. Clinical pharmacokinetics of fluconazole. Clin. Pharmacokinet. 24:10-27.
4. Grant, S. M., and S. P. Clissold. 1990. Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in superficial and systemic mycoses. Drugs 39:877-916.
5. Gulick, R. M., J. Mellors, D. Havlir, J. Eron, C. Gonzales, D. McMahon, D. Richman, F. Valentine, J. Rooney, L. Jonas, A. Meiborn, E. Emini, J. Chodakewitz. 1996. Potent and sustained antiretroviral activity of indinavir (IDV) zidovudine (ZDV) and lamivudine (3TC), abstr. Th.B.931. In Abstracts of the XI International Conference on AIDS.
6. McCrea, J., E. Woolf, A. Sterrett, C. Matthews, P. Deutsch, K. Yen, S. Waldman, and T. Bjornsson. 1996. Effects of ketoconazole and other P-450 inhibitors on the pharmacokinetics of indinavir. Pharm. Res. 13(Suppl.): S485.
7. Shaw, J. T. B., M. Tarbit, and P. Troke. 1987. Cytochrome P450 mediated sterol synthesis and metabolism: differences in sensitivity of fluconazole and other azoles, p. 125-139. In R. A. Fromtling (ed.), Recent trends in the discovery, development and evaluation of antifungal agents. J. R. Prous Science Publishers, S.A., Barcelona, Spain.
8. Steigbigel, R., P. Berry, H. Toppler, J. Mellors, G. Drusano, R. Leavitt, C. Hildebrand, L. Jonas, M. Nessly, P. Deutsch, and J. Chodakewitz. 1996. Extended follow-up of patients in a study of indinavir at 800 mg q8h (2.4 G/D), 1000 mg q8h (3.0 G/D) and 800 mg q6h (3.2 G/D), abstr. Mo.B.412. In Abstracts of the XI International Conference on AIDS.
9. Tomasko, L., et al. 1994. Comparison of two modeling procedures for the three-period, two treatment crossover pharmacokinetic drug interaction study. In XVIIth International Biometric Conference.
10. Woolf, E., T. Au, H. Haddix, and B. Matuszewski. 1995. Determination of L-735524, an human immunodeficiency virus protease inhibitor, in human plasma and urine via high-performance liquid chromatography with column switching. J. Chromatogr. A 692:45-52.
11. Yeh, K., and R. Small. 1989. Pharmacokinetic evaluation of stable piecewise cubic polynomials as numerical integration functions. J. Pharmacokinet. Biopharm. 17:721-740.